natasha persaud

1 week ago | renalandurologynews.com | natasha persaud

An acellular tissue engineered vessel (ATEV™) provides better functional patency and usability for hemodialysis vascular access than an autologous arteriovenous fistula (AVF) in women in general and men with obesity and diabetes — patients at high-risk for vascular access maturation failure. An investigator presented results from a secondary analysis of a pivotal phase 3 clinical trial at the Society for Vascular Surgery vascular annual meeting (VAM25) in New Orleans, Louisiana.

2 weeks ago | renalandurologynews.com | natasha persaud

The survival advantage of deceased-donor kidney transplantation does not apply to every patient and every donor organ, investigators revealed at the 62th European Renal Association (ERA) congress in Vienna, Austria. Older and higher-risk patients may live as long by remaining on dialysis.

2 weeks ago | renalandurologynews.com | natasha persaud

In patients with immunoglobulin A nephropathy (IgAN), higher levels of proteinuria and lower baseline estimated glomerular filtration rate (eGFR) are strongly associated with adverse kidney outcomes — even at proteinuria levels previously considered low-risk, according to investigators.

2 weeks ago | renalandurologynews.com | natasha persaud

The combination of finerenone, a nonsteroidal mineralocorticoid receptor antagonist (nsMRA), and empagliflozin, a sodium-glucose cotransporter-2 inhibitor (SGLT2i), leads to greater albuminuria reduction with good safety than either treatment alone in patients with stage G2-3 chronic kidney disease (CKD) and type 2 diabetes.

3 weeks ago | renalandurologynews.com | natasha persaud

Complement activation markers, particularly C4d and the C4d/C4 ratio, are strongly associated with both clinical and histopathologic response to immunosuppressive treatment in proliferative lupus nephritis (PLN), according to new research. In a retrospective single-center study of 77 patients with biopsy-confirmed active lupus nephritis (LN), Agneta Zickert, MD, PhD, of Karolinska Institute in Stockholm, Sweden, and colleagues analyzed complement marker trends before and after treatment.